Invega Sustenna News and Research

RSS
Advancing safety in healthcare products

Advancing safety in healthcare products

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Alkermes reports 38% of year-over-year revenue growth from key products

Alkermes reports 38% of year-over-year revenue growth from key products

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

New Australian drug approvals subject to budget cuts

New Australian drug approvals subject to budget cuts

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Elan total revenue increases 10% to $579.4 million for first half of 2010

Elan total revenue increases 10% to $579.4 million for first half of 2010

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Generic erosion to decrease branded atypical antipsychotics schizophrenia drug market to $5.2B

Generic erosion to decrease branded atypical antipsychotics schizophrenia drug market to $5.2B

Elan announces fiscal 2009 third-quarter results

Elan announces fiscal 2009 third-quarter results